People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists

Abroad (travel likely)Recruiting

Conditions

Multiple Sclerosis

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Northwestern Memorial Hospital, Chicago, Illinois, United States
Contact: Study coordinator (Dylan Rice, BA) · dylan.rice@northwestern.edu · 240-362-4800
Contact: Study coordinator (Caroline Gebczak, BS) · caroline.gebczak@northwestern.edu · 630-313-0470
Contact: Principal Investigator (Farrah J Mateen, MD, PhD)

Study leads

Farrah J Mateen
Principal Investigator
Northwestern University

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)

Multiple Sclerosis

Abroad (travel likely)RecruitingPHASE2

Bihać, Bosnia and Herzegovina · Sarajevo, Bosnia and Herzegovina

Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype

Multiple Sclerosis · Sleep · Pain

Abroad (travel likely)RecruitingPHASE2

Ann Arbor, United States

Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS)

Multiple Sclerosis

Abroad (travel likely)Recruiting

Bethesda, United States

Hyperpolarized Carbon Metabolic Imaging in Multiple Sclerosis

Multiple Sclerosis · RRMS · Relapsing Remitting MS

Abroad (travel likely)RecruitingPHASE2

San Francisco, United States